Classical midgut carcinoids are serotonin-secreting tumors derived from enterochromaffin cells in the gut. Metastatic disease represents a therapeutic challenge and immunotherapy implies a novel approach for treatment. In order to define antigens suitable for T-cell therapy with a preferential expression in midgut carcinoid tissue a broad screening of genes with preferential neuroendocrine restriction, genes described as over-expressed in various malignancies, and genes encoding cancer-testis associated antigens was performed. The expression of 32 genes was analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 28 midgut carcinoid specimens, in the cell line BON and in normal tissues. Immunohistochemistry (IHC) was used to evaluate protein expression. Expression is shown of genes that have previously not been observed in midgut carcinoid tumors, such as Survivin and GAGEs. Also the expression is confirmed of genes that encode pivotal proteins in enterochromaffin cells, such as TPH1 and VMAT1, and their tissue-restricted expression is indicated. In addition, gene expression of IA-2 and CDX-2 in normal gastrointestinal (GI) tract and in tumor is shown. Protein expression of TPH, VMAT1, and Survivin was detected in tumor tissue. This study elucidates that TPH1, VMAT1, and Survivin should be further investigated as potential target antigens for T cell-mediated immunotherapy of midgut carcinoids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02841860510007404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome.
Endocr Relat Cancer
December 2024
J Hofland, Internal Medicine, Erasmus MC, Rotterdam, Netherlands.
Article Synopsis
- - Midgut neuroendocrine tumors (NET) are linked to enterochromaffin cells and have shown a unique fecal microbial signature in patients, indicating an altered gut microbiome compared to healthy controls.
- - A study involving sequencing of fecal samples from 60 NET patients and 20 matched controls revealed specific differences in microbial communities, with 16 species and 18 pathways significantly varying between groups, yet no notable differences in microbial composition were found between patients with and without carcinoid syndrome (CS).
- - The research identifies potential microbial signatures that could serve as biomarkers for diagnosing midgut NET and distinguishing between patients with and without CS, with high accuracy in predicting presence based on microbial pathways and species.
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs.
JAMA Oncol
December 2024
University of Toronto, Toronto, Ontario, Canada.
Article Synopsis
- Evidence-based treatment for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) requires personalized decisions that take into account individual patient and cancer characteristics. !* -
- A multidisciplinary panel reviewed 131 publications to develop a guidance document with 24 recommendations and 5 good clinical practice statements focusing on diagnostic features and biomarkers for managing unresectable or metastatic GEP-NENs. !* -
- The document emphasizes treatment strategies based on tumor characteristics and specific biomarkers, and it received endorsements from major neuroendocrine tumor organizations. !*
Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment.
EJNMMI Rep
September 2024
Department of Radiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Purpose: Lutetium-177-Dotatate (Lutathera) is a combined radionuclide-peptide that is FDA-approved for the treatment of well-differentiated, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumors. Carcinoid crisis is a rare, but potentially life-threatening risk of this radiopharmaceutical, of which prompt recognition and treatment is essential to reducing morbidity. This manuscript provides an overview of the topic to promote awareness of this adverse event, with emphasis on early recognition and management.
View Article and Find Full Text PDFRadioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety.
Semin Nucl Med
July 2024
Endocrinology Unit, Department of Clinical and Molecular Medicine, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Neuroendocrine neoplasms (NENs), arising from various sites, present therapeutic challenges. Radioligand therapy (RLT) is effective for unresectable/metastatic NENs with increased somatostatin receptor uptake. While evidence supports RLT's efficacy in midgut NETs, its role in lung NETs remains underexplored.
View Article and Find Full Text PDFMidgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature.
Eur J Cancer
January 2024
ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center and Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
Rationale: When compared to other types of cancer, the prevalence of midgut neuroendocrine tumors (NET) has disproportionally increased over the past decades. To date, there has been very little progress in discovering (epi)genetic drivers and treatment options for these tumors. Recent microbiome research has revealed that enteroendocrine cells communicate with the intestinal microbiome and has provided novel treatment targets for various other cancer types.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!